{"ticker": {"uuid": "b400ee5a-b4f9-4598-9405-824cbd01b698", "symbol": "MTVA", "name": "MetaVia Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "MTVA Stock Jumps As Obesity Drug Trial Hits Key Milestone", "summary": "MetaVia Inc.'s stock (MTVA) surged by approximately 11% after the company announced a significant milestone in its phase 1 obesity drug trial for DA-1726, with all active patients completing dose titration. This early success has fueled strong trading interest and volatility in t", "url": "https://stockstotrade.com/news/metavia-inc-mtva-news-2026_07_13/", "source_name": "StocksToTrade", "published_at": "2026-07-13T17:39:44", "published_display": "13 Jul 2026 17:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "MetaVia (MTVA) Emerging Growth Virtual Conference Summary", "summary": "This article summarizes MetaVia's Emerging Growth Virtual Conference, highlighting the significant market opportunities in cardiometabolic diseases like obesity and MASH. It details clinical developments for DA-1726 and Vanoglipel, showcasing their efficacy and safety profiles. T", "url": "https://quartr.com/events/metavia-mtva-emerging-growth-virtual-conference_F6VKlQkg", "source_name": "Quartr", "published_at": "2026-07-11T19:44:50", "published_display": "11 Jul 2026 19:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia (MTVA) Q4 2025 earnings summary", "summary": "MetaVia (MTVA) reported significant progress in its cardiometabolic portfolio in Q4 2025, with positive Phase 1 data for DA-1726 for obesity and Phase 2a results for vanoglipel in MASH. The company also strengthened its intellectual property. Financially, MetaVia reduced its net ", "url": "https://quartr.com/events/metavia-inc-mtva-q4-2025_F6VKQNOk", "source_name": "Quartr", "published_at": "2026-07-11T06:41:20", "published_display": "11 Jul 2026 06:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia (MTVA) Investor presentation Summary", "summary": "MetaVia's investor presentation on March 26, 2026, highlighted significant market opportunities in obesity and MASH, projecting substantial market values by 2030. The company presented promising clinical progress for its drug candidates, DA-1726 and Vanoglipel, showcasing their e", "url": "https://quartr.com/events/metavia-mtva-investor-presentation_F6VKl2lJ", "source_name": "Quartr", "published_at": "2026-07-11T06:39:40", "published_display": "11 Jul 2026 06:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia (MTVA) Proxy filing Summary", "summary": "", "url": "https://news.google.com/rss/articles/CBMickFVX3lxTE9WNjIzZEN1UWJHU3d2N0tuNjlNd1ZCT1lreWtiMVh0NnZLdlViMWRaSTZXZWFEUndZaXFhRDNTUnNqV1pUWEtLS2F0aVZMS1NfbUIzR284SmdxUVRPU3hEMEJ0eEJHQ0UxZUhqb2wzV0ZvQQ?oc=5", "source_name": "Quartr", "published_at": "2026-07-11T01:22:06+00:00", "published_display": "11 Jul 2026 01:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia (MTVA) Emerging Growth Conference 93 Summary", "summary": "MetaVia (MTVA) presented a summary of its Emerging Growth Conference 93, highlighting key clinical updates for DA-1726 and vanoglipol. DA-1726 showed no heart rate abnormalities and a \"textbook-like\" PK profile, with Phase I part three ongoing. Vanoglipol met primary endpoints in", "url": "https://quartr.com/events/metavia-inc-mtva-emerging-growth-conference-93_F6VKl0rc", "source_name": "Quartr", "published_at": "2026-07-11T01:39:40", "published_display": "11 Jul 2026 01:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maxim Group Maintains MetaVia(MTVA.US) With Buy Rating, Maintains Target Price $8", "summary": "Maxim Group has reiterated its Buy rating for MetaVia (MTVA.US) and maintained its price target at $8. This indicates continued confidence from the analyst firm in the company's performance and future prospects.", "url": "https://www.moomoo.com/news/post/72791198/maxim-group-maintains-metavia-mtvaus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-07-10T20:11:09", "published_display": "10 Jul 2026 20:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates MetaVia stock rating on dose milestone By Investing.com", "summary": "H.C. Wainwright has reiterated its Buy rating and a $20.00 price target for MetaVia (NASDAQ:MTVA) after the company announced that all active patients in its Phase 1 clinical trials for the obesity treatment DA-1726 successfully reached the highest target doses. While this dose e", "url": "https://ca.investing.com/news/stock-market-news/hc-wainwright-reiterates-metavia-stock-rating-on-dose-milestone-93CH-4729078", "source_name": "Investing.com Canada", "published_at": "2026-07-10T12:09:58", "published_display": "10 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 69, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia reaches highest target doses in Phase 1 obesity trial", "summary": "MetaVia Inc. has announced that all active patients in Part 3 of its Phase 1 clinical trial for DA-1726, an obesity treatment, have successfully completed dose titration and are now receiving the highest target doses of 48 mg and 64 mg. This progress keeps the company on track to", "url": "https://scanx.trade/stock-market-news/ipo/metavia-files-prospectus-for-4m-common-shares-offering/44572415", "source_name": "scanx.trade", "published_at": "2026-07-09T14:39:20", "published_display": "09 Jul 2026 14:39", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia Says Patients on Experimental Obesity Drug Reach Highest Target Doses in Phase 1 Trial", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/metavia-says-patients-experimental-obesity-125824529.html", "source_name": "MT Newswires", "published_at": "2026-07-09T12:58:24+00:00", "published_display": "09 Jul 2026 12:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia completes dose titration in obesity drug trial", "summary": "MetaVia Inc. announced that all active patients in Part 3 of its Phase 1 clinical trial for the obesity treatment candidate DA-1726 have completed dose titration, reaching target doses of 48 mg and 64 mg. The trial evaluated different dose-escalation strategies in approximately 4", "url": "https://www.investing.com/news/company-news/metavia-completes-dose-titration-in-obesity-drug-trial-93CH-4784108", "source_name": "Investing.com", "published_at": "2026-07-09T13:39:20", "published_display": "09 Jul 2026 13:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity", "summary": "MetaVia Inc. announced the successful completion of dose titration for all active patients in Part 3 of its Phase 1 clinical trial of DA-1726, an oxyntomodulin analog for obesity treatment. Patients in both cohorts have reached their highest target doses of 48 mg and 64 mg, indic", "url": "https://www.prnewswire.com/news-releases/metavia-announces-completion-of-dose-titration-in-phase-1-part-3-study-of-da-1726-for-the-treatment-of-obesity-302821448.html", "source_name": "PR Newswire", "published_at": "2026-07-09T12:39:20", "published_display": "09 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia completes dose titration in Phase 1 Part 3; topline data on track for Q4 2026", "summary": "MetaVia has announced the completion of dose titration for all active patients in Phase 1 Part 3 of its clinical trial, with patients reaching target doses of 48 mg and 64 mg. The company utilized two titration cohorts to optimize tolerability. Topline data for this part of the s", "url": "https://www.tradingview.com/news/tradingview:60c641cc8bc26:0-metavia-completes-dose-titration-in-phase-1-part-3-topline-data-on-track-for-q4-2026/", "source_name": "TradingView", "published_at": "2026-07-09T12:39:20", "published_display": "09 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia (NASDAQ: MTVA) completes DA-1726 Phase 1 dose titration milestone", "summary": "MetaVia Inc. announced the successful completion of dose titration for all active patients in Part 3 of its Phase 1 clinical trial for DA-1726, an obesity treatment. Patients are now receiving the highest target doses of 48 mg and 64 mg, indicating favorable tolerability and effi", "url": "https://www.stocktitan.net/sec-filings/MTVA/8-k-meta-via-inc-reports-material-event-6d49017764e7.html", "source_name": "Stock Titan", "published_at": "2026-07-09T12:39:20", "published_display": "09 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia(MTVA) Stock Options Chain | Quotes & News", "summary": "The article provides information related to MetaVia (MTVA) stock, specifically focusing on its options chain, quotes, and news. It indicates that the content is a document, suggesting it contains detailed data or reports regarding MTVA's financial instruments and market performan", "url": "https://www.moomoo.com/stock/MTVA-US/options-chain?chain_id=Name1K9-3FXPhg.1kr5l7g&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A57,%22f%22%3A%22www.moomoo.com%2Fstock%2F0262-BMS%22%7D", "source_name": "Moomoo", "published_at": "2026-07-07T06:09:36", "published_display": "07 Jul 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia Company Profile & Introduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-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?oc=5", "source_name": "Moomoo", "published_at": "2026-07-04T10:02:35+00:00", "published_display": "04 Jul 2026 10:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 424B5 MetaVia Inc For: 2 July By Investing.com", "summary": "This article from Investing.com reports on the filing of Form 424B5 by MetaVia Inc. on July 2, 2026. The brief entry provides the company name and the filing date, indicating a regulatory update related to MetaVia Inc. The article is very concise, primarily serving as a notificat", "url": "https://uk.investing.com/news/stock-market-news/form-424b5-metavia-inc-for-2-july-93CH-4755621", "source_name": "Investing.com UK", "published_at": "2026-07-02T21:20:00", "published_display": "02 Jul 2026 21:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Metavia (NASDAQ: MTVA) ups ATM offering limit to $4.0M", "summary": "Metavia Inc. (NASDAQ: MTVA) has increased its At-The-Market (ATM) offering limit to $4.0 million, up from a previous ceiling of $2.3 million. The company has already sold $2,126,303 of common stock under the sales agreement with Ladenburg Thalmann & Co. Inc. This move expands Met", "url": "https://www.stocktitan.net/sec-filings/MTVA/424b5-meta-via-inc-prospectus-supplement-debt-securities-9a428cea2526.html", "source_name": "Stock Titan", "published_at": "2026-07-02T19:40:13", "published_display": "02 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] MetaVia Inc. Reports Material Event", "summary": "MetaVia Inc. has filed an 8-K report announcing a prospectus supplement related to its existing \"at-the-market\" equity program. The company may sell up to $4,000,000 of common stock through Ladenburg Thalmann & Co. Inc. The filing includes a legal opinion from Honigman LLP regard", "url": "https://www.stocktitan.net/sec-filings/MTVA/8-k-meta-via-inc-reports-material-event-011a5f59109e.html", "source_name": "Stock Titan", "published_at": "2026-07-02T19:40:12", "published_display": "02 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia Inc. Financial Disclosures & SEC Filings", "summary": "This article provides a comprehensive list of MetaVia Inc.'s financial disclosures and SEC filings, including quarterly and annual reports, earnings releases, and investor presentations from 2023 to 2026. These documents detail the company's clinical progress, financial performan", "url": "https://www.tradingview.com/symbols/BOATS-MTVA/documents/", "source_name": "TradingView", "published_at": "2026-07-01T09:10:51", "published_display": "01 Jul 2026 09:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OTC Markets Hosts Virtual Investor Presentation with HH Kim, CEO and President, and Marshall Woodworth, CFO of MetaVia, with David Bautz, PhD, Senior Analyst at Zacks SCR", "summary": "MetaVia's CEO, HH Kim, and CFO, Marshall Woodworth, discussed their strategic vision with Zacks SCR's David Bautz, focusing on their obesity drug DA-1726 and MASH drug danuglipron. They highlighted DA-1726's GLP-1/glucagon dual agonism, aiming for a favorable balance to minimize ", "url": "https://scr.zacks.com/news/news-details/2026/OTC-Markets-Life-Sciences-Investor-Forum-MetaVia-CEO-HH-Kim-and-CFO-Marshall-Woodworth-with-Zacks-SCRs-David-Bautz/default.aspx", "source_name": "Zacks Small Cap Research", "published_at": "2026-06-30T22:10:51", "published_display": "30 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OTC Markets Life Sciences Investor Forum: MetaVia CEO HH Kim and CFO Marshall Woodworth with Zacks SCR's David Bautz", "summary": "MetaVia's CEO HH Kim and CFO Marshall Woodworth discussed the company's strategic vision, focusing on obesity and MASH treatments. They highlighted the dual-agonist drug DA-1726 for obesity, emphasizing its GLP-1/glucagon balance and promising early clinical data with fewer side ", "url": "https://finance.yahoo.com/healthcare/articles/otc-markets-life-sciences-investor-144200451.html", "source_name": "Market source", "published_at": "2026-06-30T15:39:28", "published_display": "30 Jun 2026 15:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia (MTVA) Stock Forum and Discussion", "summary": "This article provides a forum for discussion and information sharing regarding MetaVia (MTVA) stock. It likely serves as a community platform for investors to exchange views, analysis, and news related to the company's financial performance and market outlook.", "url": "https://www.moomoo.com/stock/MTVA-US/community?from=share&stockId=86135569367206", "source_name": "Moomoo", "published_at": "2026-06-28T02:09:45", "published_display": "28 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of MetaVia Inc. \u2013 NASDAQ:MTVA", "summary": "This article provides a financial observation on MetaVia Inc. (NASDAQ: MTVA) focusing on its enterprise value to EBITDA forward metric. The content directly displays this specific financial ratio for the company, indicating a focus on fundamental analysis.", "url": "https://www.tradingview.com/symbols/NASDAQ-MTVA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T15:10:51", "published_display": "26 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia Inc. Actuals & Estimates (NASDAQ:MTVA)", "summary": "This article provides an overview of MetaVia Inc. (NASDAQ: MTVA) stock, including its current price, market capitalization, performance trends, and analyst forecasts. It details financial actuals and estimates, along with key information such as earnings reports, revenue, net inc", "url": "https://www.tradingview.com/symbols/NASDAQ-MTVA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T14:12:43", "published_display": "26 Jun 2026 14:12", "sentiment": "negative", "sentiment_pct": 33, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of MetaVia Inc. \u2013 NASDAQ:MTVA", "summary": "This article provides a financial snapshot for MetaVia Inc. (NASDAQ: MTVA), focusing on its enterprise value to revenue forward metric. It details that the market for MTVA is closed with no trades, offering a general overview of its financials within the biotechnology and health ", "url": "https://www.tradingview.com/symbols/NASDAQ-MTVA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T01:40:29", "published_display": "26 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of MetaVia Inc. \u2013 NASDAQ:MTVA", "summary": "This article provides the \"Price to sales forward\" value for MetaVia Inc. (NASDAQ: MTVA). It lists the period, value, change, and percentage change. The data is presented in a table format indicating it was \"Made by humans.\"", "url": "https://www.tradingview.com/symbols/NASDAQ-MTVA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T01:40:11", "published_display": "26 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia Inc (MTVA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "TradingKey provides an earnings forecast for MetaVia Inc (MTVA), detailing analyst ratings, price targets, and past and projected EPS. Based on two analysts, MetaVia Inc receives a \"Buy\" rating with a target price indicating significant upside potential. The report also lists pee", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mtva/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T21:11:22", "published_display": "17 Jun 2026 21:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia Inc (MTVA) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for MetaVia Inc (MTVA), detailing its current stock price, market cap, and highlighting that relevant data for key valuation metrics like P/E, P/B, P/S, and P/CF have not yet been disclosed by the company. It notes the stock's recent per", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mtva/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T21:11:22", "published_display": "17 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MTVA: Vanoglipel and DA-1726 Data Presented at ADA 2026 Scientific Sessions", "summary": "MetaVia, Inc. (MTVA) presented new late-breaking data on DA-1726 and vanoglipel at the American Diabetes Association (ADA) 2026 Scientific Sessions. The data included positive pharmacokinetic results for DA-1726 supporting once-weekly dosing and synergistic effects of vanoglipel ", "url": "https://scr.zacks.com/news/news-details/2026/MTVA-Vanoglipel-and-DA-1726-Data-Presented-at-ADA-2026-Scientific-Sessions-article/default.aspx", "source_name": "Zacks Small Cap Research", "published_at": "2026-06-17T17:11:26", "published_display": "17 Jun 2026 17:11", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/metavia-highlight-novel-obesity-metabolic-123100572.html", "source_name": "PR Newswire", "published_at": "2026-06-17T12:31:00+00:00", "published_display": "17 Jun 2026 12:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia CEO joins live investor forum on obesity therapies June 24", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQMTdoTy1CS19maTkyaXJfQ0ppVDhkQkRvcUpFODJYX1FUeU16X09sRkIyVU1HQTNkMDRydkwzNUhydHBZOVNSTVhLeW13bGZnRklQMTZmQkVpUW9YMkRoQTI5a0k4aEtUM1B5Rno2RXpCd1c4Q0lPekhXUEJOSHlZZmJEN0JEV1pZUkV5S3JiMXFobFN3eUxuWDU5bmVNQ0xvVXE3TUQzUU5XRVN3MlZjamtSWXpQR3FS?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia (NASDAQ: MTVA) investors back reverse split and equity plan changes", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPM2RZYTh0dldRTnJEbWtzSjNNem5sbUVHdncyVUdKRVVfMm16cy1hTnFqNV9vM2lUTmM3UGw5X05KOE94c2xVR2x6VWd0NUZERU5iOE1WSFl3ekJFU0NwcFpic3ZnaFRORzlFalFjSloxSV9zenRYNkszZnM4U29zR0MtdDV3N3Z4dXBJbWN1dkxtTHdMVDZhS3EzX3hzOE1WQTVv?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia (MTVA) director gets 17,186 RSUs vesting in 2027", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPZ1JPc0Izdlo1NW5LX3VTcFByTWZiZDIzUm9ZNFpQWEg0c3FEeXZUYWtEd1BjQmt2Tk9SNnBJRVVBQTB1OC1DcWRITXFFOU9wWG5aZkhZTDg5T3djQ2VNNVdwMzExLXJLVTJvaElaZWNtQXkwbVFVWHdadEFWRS1UcC1STjhZbDVLR0hSeVgxODlLemlJb05pd0dNekRoSHhWei00N1dNZF9lUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia Inc. (MTVA) director receives 17,186-share restricted stock grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPM3RfTkpkU0J5SWNlaGFZMkY3aHE3Q2p5TElVTWM4bHE2MS1ycFA2M0EwQUJ1LWVncjlycE50WTdvaXRJaW1DLXRUVjNhVFZzWnBrdHB6UWhBOHhiLTEzSkN2aTFNb284bzVWZ0hXVkZMOGJjc1dwLVZYZThZN25VdlVxdmd1c2h5d0VEaWwwWmNxWThLeUo2V0tDQy1PN0hoeDJjeXd2WjVQUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MTVA Stock Price and Chart \u2014 NASDAQ:MTVA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5LaWlJaTc2TGItbXRoODNjRXNSeEx4UTkzdmdFdVpvdnJVTFFHYVZ2NVhLLUYtNE9UNEJ4a0RGdEhYTzFVYTYzMlA4ajFWejdQQXNob19SbmY0SWV2?oc=5", "source_name": "TradingView", "published_at": "2026-06-06T07:00:00+00:00", "published_display": "06 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hear MetaVia discuss new obesity and metabolic therapies at June 11 webcast", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOMkZvVjJNWXVud055MnNDVzhsNDE0Mml1VEJNYzJZbDBsUzNwWlN5Z3ZuSzBVNW1WNWZWNV9GSmt2eFVFSE43WlV6UnV2c2tZMVN4YlluaG1GWlRIM3pXOWlvVWJxbUtrYXNXamFYUThVeHJhTVJSTzk5bUtmcWQxaWNHY3ZzdFdKN2J1MzZBbHV5V2xvVVlYSjlIeW1VdHc2RFZRMG4zMHZTRlBhUGcxX3V5aEg0UkZC?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia obesity trial shows 9.1% weight loss, liver shifts", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNSGRiaE9zYmdCNzk3N2Y1NUYzX2NPM2Rwdk9sZng3ZDk1NjNIMGoyOGFfMGtXU2x6b3JUYkFaY0Z5MktOdEZEWnVfTFZjU0dJUnN5b1RlWDJDd1pQUTVuOGlxOUVDYk9ueHRRWm4yUlVoSlhvWWRQRC1BU0dBNDdhUDlqZlNESDFjNWhyeHBmUXluUnZvT1psUUVhWE5maFprY2RGWVhmY043U1l3eDByQk9ETHNJcWptNEZQYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia MTVA Stock Soars On ADA 2026 Cardio Breakthrough Buzz", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTFBRb05yeEdxTE16ZEYyaVllVUJiMWg5TThYR2dHM2tUZi1waGtmbllPekN4OEgzZ0pnS2tXRDBSa05HZFlYNExOejlRR1Bwb0JEOUVjcE1NbUFxMk9VSEZpZnhLZmdhOHhLSHJrQ19hVUI?oc=5", "source_name": "timothysykes.com", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia (MTVA) jumps 45.9% as traders react to ADA 2026 late-breaking poster news", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQSndtOEJhbjN2Y09IQVZ2VGlYckE0SnZRaVpDajNKaGEyckdGNEl1NzBLVEg4Y0hBNkJ1TFZhczFUUWZKMV9kRGRIT29IbjZ3Ni1hWV9Pc2VCbXcteGRfTGpzSGlTZVRKMTI2VnVVTUpaQ1FndGVlWFRmYm9TRWY0VzFrZ1FjX1JRdy1lbHBwTXNNYkNGdDhkQWkyaU9hOVpkRjBmSXVWbEJEZENPUmFNV2dKOFVTT05nSlFicQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxQR0VLOWEzdEdFV2hGRE9vMmo2ckowU1hjRm54LU1rVVZ4a1lWQS13YzZvdDlXbllmekhlNHpETVZBWEY4b1F2dkJ2dm8xamt6dElkVVhlLWFNakI1U3JEZUVOQjY0YVBUbDJRbnZDR0VZQjllZEYzRGhyLWowOEFud2FRUWg3NkRRQWY0MTlUWDc4QXZXd25TTlNZRHpvMzVrR3NWOGUteFZJMlItOEpvMG40c2ZSN2N3NmM5UWprcENmeExEVHlaaWVlWnFLVmxwRWlKcA?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "MetaVia Inc. Announces 1-for-11 Reverse Stock Split", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPTzVBN1pwTWFCcTIyelkyeGNuTm55a2pQRHNSNEVhMUxWQ1A4cC13dlY5elVqRUJSczMtNEFTdm1ZbENMVVFrX0Y5OVBMdEJXLVVlamh0QkRiM2RUUHVUSlRZNFZqSEZMRTdZbUJWTjBpZGE2a3h6a2hPZkVNeGJCLWtOR01ZdDZMZjZ2Ym1kUHByaEN0dXpvNXkwUEFReGVaSFZ3dlpRVl82Zw?oc=5", "source_name": "PR Newswire", "published_at": "2025-12-02T08:00:00+00:00", "published_display": "02 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MTVA SEC Filings - MetaVia Inc 10-K, 10-Q, 8-K Forms", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTFBJR3d5RjVVWEo4VlBRX3A5bmVXcXlwdldYMmpsSUhld25jLW9KOEtoRUhycGF6SnBjZ240V19MZ2FlbWp5cThHd1BIUEFGMElBVElVVGx3RQ?oc=5", "source_name": "Stock Titan", "published_at": "2025-06-29T18:13:25+00:00", "published_display": "29 Jun 2025 18:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia (MTVA) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFAxa3hBRzJzcFVpbHNtUC1iNGhjYXlJVURmVHByd2QySTg5bjViVzNPV1VYTS1nR3NtcWY4MUdUYm53SWMxX04zTjdCREo3RFhxemtF?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T15:16:20+00:00", "published_display": "25 Apr 2025 15:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "MTVA Stock Jumps As Obesity Drug Trial Hits Key Milestone", "summary": "MetaVia Inc.'s stock (MTVA) surged by approximately 11% after the company announced a significant milestone in its phase 1 obesity drug trial for DA-1726, with all active patients completing dose titration. This early success has fueled strong trading interest and volatility in t", "url": "https://stockstotrade.com/news/metavia-inc-mtva-news-2026_07_13/", "source_name": "StocksToTrade", "published_at": "2026-07-13T17:39:44", "published_display": "13 Jul 2026 17:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia (MTVA) Emerging Growth Virtual Conference Summary", "summary": "This article summarizes MetaVia's Emerging Growth Virtual Conference, highlighting the significant market opportunities in cardiometabolic diseases like obesity and MASH. It details clinical developments for DA-1726 and Vanoglipel, showcasing their efficacy and safety profiles. T", "url": "https://quartr.com/events/metavia-mtva-emerging-growth-virtual-conference_F6VKlQkg", "source_name": "Quartr", "published_at": "2026-07-11T19:44:50", "published_display": "11 Jul 2026 19:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia (MTVA) Q4 2025 earnings summary", "summary": "MetaVia (MTVA) reported significant progress in its cardiometabolic portfolio in Q4 2025, with positive Phase 1 data for DA-1726 for obesity and Phase 2a results for vanoglipel in MASH. The company also strengthened its intellectual property. Financially, MetaVia reduced its net ", "url": "https://quartr.com/events/metavia-inc-mtva-q4-2025_F6VKQNOk", "source_name": "Quartr", "published_at": "2026-07-11T06:41:20", "published_display": "11 Jul 2026 06:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia (MTVA) Investor presentation Summary", "summary": "MetaVia's investor presentation on March 26, 2026, highlighted significant market opportunities in obesity and MASH, projecting substantial market values by 2030. The company presented promising clinical progress for its drug candidates, DA-1726 and Vanoglipel, showcasing their e", "url": "https://quartr.com/events/metavia-mtva-investor-presentation_F6VKl2lJ", "source_name": "Quartr", "published_at": "2026-07-11T06:39:40", "published_display": "11 Jul 2026 06:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia (MTVA) Proxy filing Summary", "summary": "", "url": "https://news.google.com/rss/articles/CBMickFVX3lxTE9WNjIzZEN1UWJHU3d2N0tuNjlNd1ZCT1lreWtiMVh0NnZLdlViMWRaSTZXZWFEUndZaXFhRDNTUnNqV1pUWEtLS2F0aVZMS1NfbUIzR284SmdxUVRPU3hEMEJ0eEJHQ0UxZUhqb2wzV0ZvQQ?oc=5", "source_name": "Quartr", "published_at": "2026-07-11T01:22:06+00:00", "published_display": "11 Jul 2026 01:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia (MTVA) Emerging Growth Conference 93 Summary", "summary": "MetaVia (MTVA) presented a summary of its Emerging Growth Conference 93, highlighting key clinical updates for DA-1726 and vanoglipol. DA-1726 showed no heart rate abnormalities and a \"textbook-like\" PK profile, with Phase I part three ongoing. Vanoglipol met primary endpoints in", "url": "https://quartr.com/events/metavia-inc-mtva-emerging-growth-conference-93_F6VKl0rc", "source_name": "Quartr", "published_at": "2026-07-11T01:39:40", "published_display": "11 Jul 2026 01:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maxim Group Maintains MetaVia(MTVA.US) With Buy Rating, Maintains Target Price $8", "summary": "Maxim Group has reiterated its Buy rating for MetaVia (MTVA.US) and maintained its price target at $8. This indicates continued confidence from the analyst firm in the company's performance and future prospects.", "url": "https://www.moomoo.com/news/post/72791198/maxim-group-maintains-metavia-mtvaus-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-07-10T20:11:09", "published_display": "10 Jul 2026 20:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates MetaVia stock rating on dose milestone By Investing.com", "summary": "H.C. Wainwright has reiterated its Buy rating and a $20.00 price target for MetaVia (NASDAQ:MTVA) after the company announced that all active patients in its Phase 1 clinical trials for the obesity treatment DA-1726 successfully reached the highest target doses. While this dose e", "url": "https://ca.investing.com/news/stock-market-news/hc-wainwright-reiterates-metavia-stock-rating-on-dose-milestone-93CH-4729078", "source_name": "Investing.com Canada", "published_at": "2026-07-10T12:09:58", "published_display": "10 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 69, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia reaches highest target doses in Phase 1 obesity trial", "summary": "MetaVia Inc. has announced that all active patients in Part 3 of its Phase 1 clinical trial for DA-1726, an obesity treatment, have successfully completed dose titration and are now receiving the highest target doses of 48 mg and 64 mg. This progress keeps the company on track to", "url": "https://scanx.trade/stock-market-news/ipo/metavia-files-prospectus-for-4m-common-shares-offering/44572415", "source_name": "scanx.trade", "published_at": "2026-07-09T14:39:20", "published_display": "09 Jul 2026 14:39", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia Says Patients on Experimental Obesity Drug Reach Highest Target Doses in Phase 1 Trial", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/metavia-says-patients-experimental-obesity-125824529.html", "source_name": "MT Newswires", "published_at": "2026-07-09T12:58:24+00:00", "published_display": "09 Jul 2026 12:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia completes dose titration in obesity drug trial", "summary": "MetaVia Inc. announced that all active patients in Part 3 of its Phase 1 clinical trial for the obesity treatment candidate DA-1726 have completed dose titration, reaching target doses of 48 mg and 64 mg. The trial evaluated different dose-escalation strategies in approximately 4", "url": "https://www.investing.com/news/company-news/metavia-completes-dose-titration-in-obesity-drug-trial-93CH-4784108", "source_name": "Investing.com", "published_at": "2026-07-09T13:39:20", "published_display": "09 Jul 2026 13:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity", "summary": "MetaVia Inc. announced the successful completion of dose titration for all active patients in Part 3 of its Phase 1 clinical trial of DA-1726, an oxyntomodulin analog for obesity treatment. Patients in both cohorts have reached their highest target doses of 48 mg and 64 mg, indic", "url": "https://www.prnewswire.com/news-releases/metavia-announces-completion-of-dose-titration-in-phase-1-part-3-study-of-da-1726-for-the-treatment-of-obesity-302821448.html", "source_name": "PR Newswire", "published_at": "2026-07-09T12:39:20", "published_display": "09 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia completes dose titration in Phase 1 Part 3; topline data on track for Q4 2026", "summary": "MetaVia has announced the completion of dose titration for all active patients in Phase 1 Part 3 of its clinical trial, with patients reaching target doses of 48 mg and 64 mg. The company utilized two titration cohorts to optimize tolerability. Topline data for this part of the s", "url": "https://www.tradingview.com/news/tradingview:60c641cc8bc26:0-metavia-completes-dose-titration-in-phase-1-part-3-topline-data-on-track-for-q4-2026/", "source_name": "TradingView", "published_at": "2026-07-09T12:39:20", "published_display": "09 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia (NASDAQ: MTVA) completes DA-1726 Phase 1 dose titration milestone", "summary": "MetaVia Inc. announced the successful completion of dose titration for all active patients in Part 3 of its Phase 1 clinical trial for DA-1726, an obesity treatment. Patients are now receiving the highest target doses of 48 mg and 64 mg, indicating favorable tolerability and effi", "url": "https://www.stocktitan.net/sec-filings/MTVA/8-k-meta-via-inc-reports-material-event-6d49017764e7.html", "source_name": "Stock Titan", "published_at": "2026-07-09T12:39:20", "published_display": "09 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia(MTVA) Stock Options Chain | Quotes & News", "summary": "The article provides information related to MetaVia (MTVA) stock, specifically focusing on its options chain, quotes, and news. It indicates that the content is a document, suggesting it contains detailed data or reports regarding MTVA's financial instruments and market performan", "url": "https://www.moomoo.com/stock/MTVA-US/options-chain?chain_id=Name1K9-3FXPhg.1kr5l7g&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A57,%22f%22%3A%22www.moomoo.com%2Fstock%2F0262-BMS%22%7D", "source_name": "Moomoo", "published_at": "2026-07-07T06:09:36", "published_display": "07 Jul 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia Company Profile & Introduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-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?oc=5", "source_name": "Moomoo", "published_at": "2026-07-04T10:02:35+00:00", "published_display": "04 Jul 2026 10:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 424B5 MetaVia Inc For: 2 July By Investing.com", "summary": "This article from Investing.com reports on the filing of Form 424B5 by MetaVia Inc. on July 2, 2026. The brief entry provides the company name and the filing date, indicating a regulatory update related to MetaVia Inc. The article is very concise, primarily serving as a notificat", "url": "https://uk.investing.com/news/stock-market-news/form-424b5-metavia-inc-for-2-july-93CH-4755621", "source_name": "Investing.com UK", "published_at": "2026-07-02T21:20:00", "published_display": "02 Jul 2026 21:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Metavia (NASDAQ: MTVA) ups ATM offering limit to $4.0M", "summary": "Metavia Inc. (NASDAQ: MTVA) has increased its At-The-Market (ATM) offering limit to $4.0 million, up from a previous ceiling of $2.3 million. The company has already sold $2,126,303 of common stock under the sales agreement with Ladenburg Thalmann & Co. Inc. This move expands Met", "url": "https://www.stocktitan.net/sec-filings/MTVA/424b5-meta-via-inc-prospectus-supplement-debt-securities-9a428cea2526.html", "source_name": "Stock Titan", "published_at": "2026-07-02T19:40:13", "published_display": "02 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] MetaVia Inc. Reports Material Event", "summary": "MetaVia Inc. has filed an 8-K report announcing a prospectus supplement related to its existing \"at-the-market\" equity program. The company may sell up to $4,000,000 of common stock through Ladenburg Thalmann & Co. Inc. The filing includes a legal opinion from Honigman LLP regard", "url": "https://www.stocktitan.net/sec-filings/MTVA/8-k-meta-via-inc-reports-material-event-011a5f59109e.html", "source_name": "Stock Titan", "published_at": "2026-07-02T19:40:12", "published_display": "02 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia Inc. Financial Disclosures & SEC Filings", "summary": "This article provides a comprehensive list of MetaVia Inc.'s financial disclosures and SEC filings, including quarterly and annual reports, earnings releases, and investor presentations from 2023 to 2026. These documents detail the company's clinical progress, financial performan", "url": "https://www.tradingview.com/symbols/BOATS-MTVA/documents/", "source_name": "TradingView", "published_at": "2026-07-01T09:10:51", "published_display": "01 Jul 2026 09:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OTC Markets Hosts Virtual Investor Presentation with HH Kim, CEO and President, and Marshall Woodworth, CFO of MetaVia, with David Bautz, PhD, Senior Analyst at Zacks SCR", "summary": "MetaVia's CEO, HH Kim, and CFO, Marshall Woodworth, discussed their strategic vision with Zacks SCR's David Bautz, focusing on their obesity drug DA-1726 and MASH drug danuglipron. They highlighted DA-1726's GLP-1/glucagon dual agonism, aiming for a favorable balance to minimize ", "url": "https://scr.zacks.com/news/news-details/2026/OTC-Markets-Life-Sciences-Investor-Forum-MetaVia-CEO-HH-Kim-and-CFO-Marshall-Woodworth-with-Zacks-SCRs-David-Bautz/default.aspx", "source_name": "Zacks Small Cap Research", "published_at": "2026-06-30T22:10:51", "published_display": "30 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OTC Markets Life Sciences Investor Forum: MetaVia CEO HH Kim and CFO Marshall Woodworth with Zacks SCR's David Bautz", "summary": "MetaVia's CEO HH Kim and CFO Marshall Woodworth discussed the company's strategic vision, focusing on obesity and MASH treatments. They highlighted the dual-agonist drug DA-1726 for obesity, emphasizing its GLP-1/glucagon balance and promising early clinical data with fewer side ", "url": "https://finance.yahoo.com/healthcare/articles/otc-markets-life-sciences-investor-144200451.html", "source_name": "Market source", "published_at": "2026-06-30T15:39:28", "published_display": "30 Jun 2026 15:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia (MTVA) Stock Forum and Discussion", "summary": "This article provides a forum for discussion and information sharing regarding MetaVia (MTVA) stock. It likely serves as a community platform for investors to exchange views, analysis, and news related to the company's financial performance and market outlook.", "url": "https://www.moomoo.com/stock/MTVA-US/community?from=share&stockId=86135569367206", "source_name": "Moomoo", "published_at": "2026-06-28T02:09:45", "published_display": "28 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of MetaVia Inc. \u2013 NASDAQ:MTVA", "summary": "This article provides a financial observation on MetaVia Inc. (NASDAQ: MTVA) focusing on its enterprise value to EBITDA forward metric. The content directly displays this specific financial ratio for the company, indicating a focus on fundamental analysis.", "url": "https://www.tradingview.com/symbols/NASDAQ-MTVA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T15:10:51", "published_display": "26 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia Inc. Actuals & Estimates (NASDAQ:MTVA)", "summary": "This article provides an overview of MetaVia Inc. (NASDAQ: MTVA) stock, including its current price, market capitalization, performance trends, and analyst forecasts. It details financial actuals and estimates, along with key information such as earnings reports, revenue, net inc", "url": "https://www.tradingview.com/symbols/NASDAQ-MTVA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T14:12:43", "published_display": "26 Jun 2026 14:12", "sentiment": "negative", "sentiment_pct": 33, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of MetaVia Inc. \u2013 NASDAQ:MTVA", "summary": "This article provides a financial snapshot for MetaVia Inc. (NASDAQ: MTVA), focusing on its enterprise value to revenue forward metric. It details that the market for MTVA is closed with no trades, offering a general overview of its financials within the biotechnology and health ", "url": "https://www.tradingview.com/symbols/NASDAQ-MTVA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T01:40:29", "published_display": "26 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of MetaVia Inc. \u2013 NASDAQ:MTVA", "summary": "This article provides the \"Price to sales forward\" value for MetaVia Inc. (NASDAQ: MTVA). It lists the period, value, change, and percentage change. The data is presented in a table format indicating it was \"Made by humans.\"", "url": "https://www.tradingview.com/symbols/NASDAQ-MTVA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T01:40:11", "published_display": "26 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia Inc (MTVA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "TradingKey provides an earnings forecast for MetaVia Inc (MTVA), detailing analyst ratings, price targets, and past and projected EPS. Based on two analysts, MetaVia Inc receives a \"Buy\" rating with a target price indicating significant upside potential. The report also lists pee", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mtva/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T21:11:22", "published_display": "17 Jun 2026 21:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia Inc (MTVA) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for MetaVia Inc (MTVA), detailing its current stock price, market cap, and highlighting that relevant data for key valuation metrics like P/E, P/B, P/S, and P/CF have not yet been disclosed by the company. It notes the stock's recent per", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mtva/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T21:11:22", "published_display": "17 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MTVA: Vanoglipel and DA-1726 Data Presented at ADA 2026 Scientific Sessions", "summary": "MetaVia, Inc. (MTVA) presented new late-breaking data on DA-1726 and vanoglipel at the American Diabetes Association (ADA) 2026 Scientific Sessions. The data included positive pharmacokinetic results for DA-1726 supporting once-weekly dosing and synergistic effects of vanoglipel ", "url": "https://scr.zacks.com/news/news-details/2026/MTVA-Vanoglipel-and-DA-1726-Data-Presented-at-ADA-2026-Scientific-Sessions-article/default.aspx", "source_name": "Zacks Small Cap Research", "published_at": "2026-06-17T17:11:26", "published_display": "17 Jun 2026 17:11", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/metavia-highlight-novel-obesity-metabolic-123100572.html", "source_name": "PR Newswire", "published_at": "2026-06-17T12:31:00+00:00", "published_display": "17 Jun 2026 12:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia CEO joins live investor forum on obesity therapies June 24", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQMTdoTy1CS19maTkyaXJfQ0ppVDhkQkRvcUpFODJYX1FUeU16X09sRkIyVU1HQTNkMDRydkwzNUhydHBZOVNSTVhLeW13bGZnRklQMTZmQkVpUW9YMkRoQTI5a0k4aEtUM1B5Rno2RXpCd1c4Q0lPekhXUEJOSHlZZmJEN0JEV1pZUkV5S3JiMXFobFN3eUxuWDU5bmVNQ0xvVXE3TUQzUU5XRVN3MlZjamtSWXpQR3FS?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia (NASDAQ: MTVA) investors back reverse split and equity plan changes", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPM2RZYTh0dldRTnJEbWtzSjNNem5sbUVHdncyVUdKRVVfMm16cy1hTnFqNV9vM2lUTmM3UGw5X05KOE94c2xVR2x6VWd0NUZERU5iOE1WSFl3ekJFU0NwcFpic3ZnaFRORzlFalFjSloxSV9zenRYNkszZnM4U29zR0MtdDV3N3Z4dXBJbWN1dkxtTHdMVDZhS3EzX3hzOE1WQTVv?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia (MTVA) director gets 17,186 RSUs vesting in 2027", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPZ1JPc0Izdlo1NW5LX3VTcFByTWZiZDIzUm9ZNFpQWEg0c3FEeXZUYWtEd1BjQmt2Tk9SNnBJRVVBQTB1OC1DcWRITXFFOU9wWG5aZkhZTDg5T3djQ2VNNVdwMzExLXJLVTJvaElaZWNtQXkwbVFVWHdadEFWRS1UcC1STjhZbDVLR0hSeVgxODlLemlJb05pd0dNekRoSHhWei00N1dNZF9lUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia Inc. (MTVA) director receives 17,186-share restricted stock grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPM3RfTkpkU0J5SWNlaGFZMkY3aHE3Q2p5TElVTWM4bHE2MS1ycFA2M0EwQUJ1LWVncjlycE50WTdvaXRJaW1DLXRUVjNhVFZzWnBrdHB6UWhBOHhiLTEzSkN2aTFNb284bzVWZ0hXVkZMOGJjc1dwLVZYZThZN25VdlVxdmd1c2h5d0VEaWwwWmNxWThLeUo2V0tDQy1PN0hoeDJjeXd2WjVQUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MTVA Stock Price and Chart \u2014 NASDAQ:MTVA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5LaWlJaTc2TGItbXRoODNjRXNSeEx4UTkzdmdFdVpvdnJVTFFHYVZ2NVhLLUYtNE9UNEJ4a0RGdEhYTzFVYTYzMlA4ajFWejdQQXNob19SbmY0SWV2?oc=5", "source_name": "TradingView", "published_at": "2026-06-06T07:00:00+00:00", "published_display": "06 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hear MetaVia discuss new obesity and metabolic therapies at June 11 webcast", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOMkZvVjJNWXVud055MnNDVzhsNDE0Mml1VEJNYzJZbDBsUzNwWlN5Z3ZuSzBVNW1WNWZWNV9GSmt2eFVFSE43WlV6UnV2c2tZMVN4YlluaG1GWlRIM3pXOWlvVWJxbUtrYXNXamFYUThVeHJhTVJSTzk5bUtmcWQxaWNHY3ZzdFdKN2J1MzZBbHV5V2xvVVlYSjlIeW1VdHc2RFZRMG4zMHZTRlBhUGcxX3V5aEg0UkZC?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia obesity trial shows 9.1% weight loss, liver shifts", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNSGRiaE9zYmdCNzk3N2Y1NUYzX2NPM2Rwdk9sZng3ZDk1NjNIMGoyOGFfMGtXU2x6b3JUYkFaY0Z5MktOdEZEWnVfTFZjU0dJUnN5b1RlWDJDd1pQUTVuOGlxOUVDYk9ueHRRWm4yUlVoSlhvWWRQRC1BU0dBNDdhUDlqZlNESDFjNWhyeHBmUXluUnZvT1psUUVhWE5maFprY2RGWVhmY043U1l3eDByQk9ETHNJcWptNEZQYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia MTVA Stock Soars On ADA 2026 Cardio Breakthrough Buzz", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTFBRb05yeEdxTE16ZEYyaVllVUJiMWg5TThYR2dHM2tUZi1waGtmbllPekN4OEgzZ0pnS2tXRDBSa05HZFlYNExOejlRR1Bwb0JEOUVjcE1NbUFxMk9VSEZpZnhLZmdhOHhLSHJrQ19hVUI?oc=5", "source_name": "timothysykes.com", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia (MTVA) jumps 45.9% as traders react to ADA 2026 late-breaking poster news", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQSndtOEJhbjN2Y09IQVZ2VGlYckE0SnZRaVpDajNKaGEyckdGNEl1NzBLVEg4Y0hBNkJ1TFZhczFUUWZKMV9kRGRIT29IbjZ3Ni1hWV9Pc2VCbXcteGRfTGpzSGlTZVRKMTI2VnVVTUpaQ1FndGVlWFRmYm9TRWY0VzFrZ1FjX1JRdy1lbHBwTXNNYkNGdDhkQWkyaU9hOVpkRjBmSXVWbEJEZENPUmFNV2dKOFVTT05nSlFicQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxQR0VLOWEzdEdFV2hGRE9vMmo2ckowU1hjRm54LU1rVVZ4a1lWQS13YzZvdDlXbllmekhlNHpETVZBWEY4b1F2dkJ2dm8xamt6dElkVVhlLWFNakI1U3JEZUVOQjY0YVBUbDJRbnZDR0VZQjllZEYzRGhyLWowOEFud2FRUWg3NkRRQWY0MTlUWDc4QXZXd25TTlNZRHpvMzVrR3NWOGUteFZJMlItOEpvMG40c2ZSN2N3NmM5UWprcENmeExEVHlaaWVlWnFLVmxwRWlKcA?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia Inc. Announces 1-for-11 Reverse Stock Split", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPTzVBN1pwTWFCcTIyelkyeGNuTm55a2pQRHNSNEVhMUxWQ1A4cC13dlY5elVqRUJSczMtNEFTdm1ZbENMVVFrX0Y5OVBMdEJXLVVlamh0QkRiM2RUUHVUSlRZNFZqSEZMRTdZbUJWTjBpZGE2a3h6a2hPZkVNeGJCLWtOR01ZdDZMZjZ2Ym1kUHByaEN0dXpvNXkwUEFReGVaSFZ3dlpRVl82Zw?oc=5", "source_name": "PR Newswire", "published_at": "2025-12-02T08:00:00+00:00", "published_display": "02 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MTVA SEC Filings - MetaVia Inc 10-K, 10-Q, 8-K Forms", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTFBJR3d5RjVVWEo4VlBRX3A5bmVXcXlwdldYMmpsSUhld25jLW9KOEtoRUhycGF6SnBjZ240V19MZ2FlbWp5cThHd1BIUEFGMElBVElVVGx3RQ?oc=5", "source_name": "Stock Titan", "published_at": "2025-06-29T18:13:25+00:00", "published_display": "29 Jun 2025 18:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MetaVia (MTVA) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFAxa3hBRzJzcFVpbHNtUC1iNGhjYXlJVURmVHByd2QySTg5bjViVzNPV1VYTS1nR3NtcWY4MUdUYm53SWMxX04zTjdCREo3RFhxemtF?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T15:16:20+00:00", "published_display": "25 Apr 2025 15:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 93, "total_relevant": 52, "sentiment_summary": {"positive": 17, "negative": 3, "neutral": 32, "score": 58, "total": 52, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 14.3, "count": 26}, {"event": "earnings", "label": "Earnings", "weight": 7.5, "count": 15}, {"event": "analyst", "label": "Analyst action", "weight": 5.3, "count": 9}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 17, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 1.78, "latest_week": "2026-07-10", "one_week_move": 20.3, "four_week_move": 2.3, "twelve_week_move": 27.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.427528, "market_dynamics_buy_signal": false, "relative_strength": -71.992416, "fair_value_gap": -92.7, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 43.0045, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+20.3% over one week, +2.3% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 67, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 11}, {"label": "TradingView", "count": 8}, {"label": "Market source", "count": 6}, {"label": "Quartr", "count": 5}, {"label": "Moomoo", "count": 4}, {"label": "PR Newswire", "count": 4}, {"label": "Zacks Small Cap Research", "count": 2}, {"label": "TradingKey", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 44}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 26}, {"label": "Earnings", "count": 15}, {"label": "Analyst action", "count": 9}, {"label": "Regulatory and legal", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "44", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+20.3% over one week, +2.3% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "MTVA Stock Jumps As Obesity Drug Trial Hits Key Milestone"}], "updated_at": "2026-07-16T00:50:08.415156+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}